-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2020, according to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer has replaced lung cancer and has become the world's most cancerous cancer
At the end of 2020, according to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer has replaced lung cancer and has become the world's most cancerous cancer
.
Breast Cancer There are four subtypes of
breast cancer, namely estrogen receptor (ER) positive, progesterone receptor (PR) positive, human epithelial growth factor receptor-2 (HER2) positive and triple negative breast cancer .
Among these breast cancer subtypes, triple negative breast cancer (TNBC) is most feared by doctors and patients
.
Triple-negative breast cancer refers to a special type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2)
.
Triple-negative breast cancer accounts for about 15% of all breast cancers and is the most dangerous type of breast cancer .
Compared with other subtypes of early breast cancer with a 5-year survival rate of more than 90%, the 5-year survival rate for early triple-negative breast cancer is only 77%, while the 5-year survival rate for advanced patients is only 14% .
Yao Beina died of triple-negative breast cancer at the age of 33 .
The treatment methods for the first three subtypes of breast cancer are now mature, such as estrogen, progesterone therapy and anti-HER2 therapy .
However, because triple-negative breast cancer tests negative for estrogen receptor, progesterone receptor, and human epithelial growth factor receptor-2, treatments for ER, PR, and HER2 are ineffective .
For this reason, chemotherapy is still the main standard treatment for TNBC .
Due to its poor prognosis, it is prone to relapse, and there are few treatment options .
Clinically, new treatment methods for triple-negative breast cancer have been studied .
Recently, a team of clinicians and scientists from the National Cancer Center of Singapore (NCCS) discovered a new treatment for triple-negative breast cancer (TNBC)
.
The research was published in the journal "Science Advances" on October 7, 2021
.
DOI: 10.
1126/sciadv.
abh2443 They found that cancer cells can switch between different cell states, being able to change from being less aggressive ("Epithelial") to being more aggressive ("Mesenchymal") , And vice versa .
The results of the study show that the neoadjuvant treatment of Bexarotene can promote the transformation of highly invasive mesenchymal cancer cells in breast cancer to low invasive epithelial cancer cells .
This allows breast tumors to respond better to subsequent chemotherapy and produce a lasting treatment effect .
This discovery led to the initiation of a three-year human clinical trial, BEXMET , to study this unconventional method of treating TNBC .
In this study, the researchers used the highly advanced genome sequencing and functional genomic capabilities of GIS and found that bexarotene (a class of drugs called retinoic acid) can transform the more aggressive "mesenchymal" cell state It is a weakly aggressive "epithelial" cell state .
This biological process is also called Mesenchymal to Epithelial Transition (MET) .
This is the first time that Bexarotene has been used to promote the MET process in preclinical breast cancer work .
In this study, the researchers found in preclinical tests in animal models that Bexarotene changed the state of TNBC cells from mesenchymal to epithelial, making TNBC cells more susceptible to conventional chemotherapy, which resulted in a longer-lasting response and thus Prevent recurrence of cancer
.
The scientific model explains the principle behind this phenomenon .
In the more aggressive mesenchymal cell state, fatty acids are oxidized to produce acetyl-CoA, which controls the genes responsible for epithelial-mesenchymal transition and cancer metastasis .
But after retinoic acid treatment, fatty acids will be stored in the form of lipids .
By preventing the ability of cancer cells to oxidize fatty acids, the less aggressive epithelial cancer cells cannot obtain aggressive behavior, and the possibility of metastasis is less .
"Cancer cells are very cunning, and there are ways to evade treatment.
The solution may be to coax them into a less aggressive state before chemotherapy, instead of directly using chemotherapy to deal with the tumor .
This is different from standard cancer treatment .
"Dr.
Tan said .
This three-year human clinical trial aims to verify the Bexarotene-induced TNBC cell status changes observed in preclinical studies , and to evaluate Bexarotene-Capecitabine (Capecitabine), which is mainly used for advanced breast cancer and colorectal cancer.
As a breast cancer rescue treatment after failure of anthracycline and taxane therapy) the tolerability and effectiveness of chemotherapy combination .
For cancer, the development cost of new oncology drugs is very high, and affordability and availability are both challenges .
And MET inducer (Bexarotene) may be a cost-effective way to treat TNBC, and may treat a wider range of other cancers
.
If this 3-year clinical trial is successful, it is really good news for the majority of women
.
Although medical technology has been advancing, the five-year survival rate of breast cancer is getting higher and higher .
However, for some breast cancer patients, the psychological damage caused by mastectomy takes a long time to be truly cured.
Therefore, for breast cancer, prevention is far more important than treatment .
Prevent us how to prevent breast cancer usually does? How do we usually prevent breast cancer? 1.
Weight control 1.
Weight control studies have shown that the risk of breast cancer in people with the highest fat content is 1.
44 times that of people with the lowest fat content .
2.
Non-smoking, non-drinking 2.
Non-smokers, non-drinking, alcoholic drinkers and smokers have an increased risk of breast cancer .
In addition, studies have shown that smoking causes cancer cells in breast cancer patients to metastasize to the lungs, thereby aggravating the condition .
3.
Exercise more 3.
Exercise more .
A case-control study published in the International journal of cancer showed that exercise at 8-10 in the morning is associated with a 26% reduction in the risk of breast cancer compared with those who do not exercise .
4.
Keep a cheerful mood.
4.
Keep a cheerful mood .
Bad emotions such as stress, anxiety and depression can easily cause endocrine disorders, leading to the occurrence of malignant tumors .
So try not to be immersed in negative emotions all the time, and actively adjust your mood .
5, breast cancer screening 5, breast cancer screening screening 40 to 50 years old to start breast cancer screening
.
A joint examination of breast B-ultrasound and mammography of mammography is performed every 1 to 2 years
.
After 70 years of age, mammography can be taken every 2 years
.
In today’s World Breast Cancer Awareness Day, I hope everyone can actively prevent breast cancer in their daily lives and keep cancer away from us .
References: Ser Yue Loo et Al, Fatty acid Oxidation druggable IS A Cellular Gateway plasticity for regulating Driving Metastasis in Breast Cancer, in Advances Science (2021) the DOI:.
10.
1126 / sciadv.
abh2443 in this message
At the end of 2020, according to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer has replaced lung cancer and has become the world's most cancerous cancer
.
Breast Cancer There are four subtypes of
breast cancer, namely estrogen receptor (ER) positive, progesterone receptor (PR) positive, human epithelial growth factor receptor-2 (HER2) positive and triple negative breast cancer .
Among these breast cancer subtypes, triple negative breast cancer (TNBC) is most feared by doctors and patients
.
Triple-negative breast cancer refers to a special type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2)
.
Triple-negative breast cancer accounts for about 15% of all breast cancers and is the most dangerous type of breast cancer .
Compared with other subtypes of early breast cancer with a 5-year survival rate of more than 90%, the 5-year survival rate for early triple-negative breast cancer is only 77%, while the 5-year survival rate for advanced patients is only 14% .
Yao Beina died of triple-negative breast cancer at the age of 33 .
The treatment methods for the first three subtypes of breast cancer are now mature, such as estrogen, progesterone therapy and anti-HER2 therapy .
However, because triple-negative breast cancer tests negative for estrogen receptor, progesterone receptor, and human epithelial growth factor receptor-2, treatments for ER, PR, and HER2 are ineffective .
For this reason, chemotherapy is still the main standard treatment for TNBC .
Due to its poor prognosis, it is prone to relapse, and there are few treatment options .
Clinically, new treatment methods for triple-negative breast cancer have been studied .
Recently, a team of clinicians and scientists from the National Cancer Center of Singapore (NCCS) discovered a new treatment for triple-negative breast cancer (TNBC)
.
The research was published in the journal "Science Advances" on October 7, 2021
.
DOI: 10.
1126/sciadv.
abh2443 They found that cancer cells can switch between different cell states, being able to change from being less aggressive ("Epithelial") to being more aggressive ("Mesenchymal") , And vice versa .
The results of the study show that the neoadjuvant treatment of Bexarotene can promote the transformation of highly invasive mesenchymal cancer cells in breast cancer to low invasive epithelial cancer cells .
This allows breast tumors to respond better to subsequent chemotherapy and produce a lasting treatment effect .
This discovery led to the initiation of a three-year human clinical trial, BEXMET , to study this unconventional method of treating TNBC .
In this study, the researchers used the highly advanced genome sequencing and functional genomic capabilities of GIS and found that bexarotene (a class of drugs called retinoic acid) can transform the more aggressive "mesenchymal" cell state It is a weakly aggressive "epithelial" cell state .
This biological process is also called Mesenchymal to Epithelial Transition (MET) .
This is the first time that Bexarotene has been used to promote the MET process in preclinical breast cancer work .
In this study, the researchers found in preclinical tests in animal models that Bexarotene changed the state of TNBC cells from mesenchymal to epithelial, making TNBC cells more susceptible to conventional chemotherapy, which resulted in a longer-lasting response and thus Prevent recurrence of cancer
.
The scientific model explains the principle behind this phenomenon .
In the more aggressive mesenchymal cell state, fatty acids are oxidized to produce acetyl-CoA, which controls the genes responsible for epithelial-mesenchymal transition and cancer metastasis .
But after retinoic acid treatment, fatty acids will be stored in the form of lipids .
By preventing the ability of cancer cells to oxidize fatty acids, the less aggressive epithelial cancer cells cannot obtain aggressive behavior, and the possibility of metastasis is less .
"Cancer cells are very cunning, and there are ways to evade treatment.
The solution may be to coax them into a less aggressive state before chemotherapy, instead of directly using chemotherapy to deal with the tumor .
This is different from standard cancer treatment .
"Dr.
Tan said .
This three-year human clinical trial aims to verify the Bexarotene-induced TNBC cell status changes observed in preclinical studies , and to evaluate Bexarotene-Capecitabine (Capecitabine), which is mainly used for advanced breast cancer and colorectal cancer.
As a breast cancer rescue treatment after failure of anthracycline and taxane therapy) the tolerability and effectiveness of chemotherapy combination .
For cancer, the development cost of new oncology drugs is very high, and affordability and availability are both challenges .
And MET inducer (Bexarotene) may be a cost-effective way to treat TNBC, and may treat a wider range of other cancers
.
If this 3-year clinical trial is successful, it is really good news for the majority of women
.
Although medical technology has been advancing, the five-year survival rate of breast cancer is getting higher and higher .
However, for some breast cancer patients, the psychological damage caused by mastectomy takes a long time to be truly cured.
Therefore, for breast cancer, prevention is far more important than treatment .
Prevent us how to prevent breast cancer usually does? How do we usually prevent breast cancer? 1.
Weight control 1.
Weight control studies have shown that the risk of breast cancer in people with the highest fat content is 1.
44 times that of people with the lowest fat content .
2.
Non-smoking, non-drinking 2.
Non-smokers, non-drinking, alcoholic drinkers and smokers have an increased risk of breast cancer .
In addition, studies have shown that smoking causes cancer cells in breast cancer patients to metastasize to the lungs, thereby aggravating the condition .
3.
Exercise more 3.
Exercise more .
A case-control study published in the International journal of cancer showed that exercise at 8-10 in the morning is associated with a 26% reduction in the risk of breast cancer compared with those who do not exercise .
4.
Keep a cheerful mood.
4.
Keep a cheerful mood .
Bad emotions such as stress, anxiety and depression can easily cause endocrine disorders, leading to the occurrence of malignant tumors .
So try not to be immersed in negative emotions all the time, and actively adjust your mood .
5, breast cancer screening 5, breast cancer screening screening 40 to 50 years old to start breast cancer screening
.
A joint examination of breast B-ultrasound and mammography of mammography is performed every 1 to 2 years
.
After 70 years of age, mammography can be taken every 2 years
.
In today’s World Breast Cancer Awareness Day, I hope everyone can actively prevent breast cancer in their daily lives and keep cancer away from us .
References: Ser Yue Loo et Al, Fatty acid Oxidation druggable IS A Cellular Gateway plasticity for regulating Driving Metastasis in Breast Cancer, in Advances Science (2021) the DOI:.
10.
1126 / sciadv.
abh2443 in this message
